Changes in ventricular remodelling and clinical status during the year following a single administration of stromal cell-derived factor-1 non-viral gene therapy in chronic ischaemic heart failure patients: the STOP-HF randomized Phase II trial

BACKGROUND: Stromal cell-derived factor-1 (SDF-1) promotes tissue repair through mechanisms of cell survival, endogenous stem cell recruitment, and vasculogenesis. Stromal Cell-Derived Factor-1 Plasmid Treatment for Patients with Heart Failure (STOP-HF) is a Phase II, double-blind, randomized, place...

Descripción completa

Detalles Bibliográficos
Autores principales: Chung, Eugene S., Miller, Leslie, Patel, Amit N., Anderson, Russell David, Mendelsohn, Farrell O., Traverse, Jay, Silver, Kevin H., Shin, Julia, Ewald, Gregory, Farr, Mary Jane, Anwaruddin, Saif, Plat, Francis, Fisher, Scott J., AuWerter, Alexander T., Pastore, Joseph M., Aras, Rahul, Penn, Marc S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2015
Materias:
FASTTrack Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4554960/
https://www.ncbi.nlm.nih.gov/pubmed/26056125
http://dx.doi.org/10.1093/eurheartj/ehv254

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4554960/
https://www.ncbi.nlm.nih.gov/pubmed/26056125
http://dx.doi.org/10.1093/eurheartj/ehv254

Ejemplares similares